Sunuuary In order to test whether circumvention of clinical resistance can be obtained in common solid tumours by targeting different drug resistance mechanisms, a phase I chnical and immunological study was designed. The purpose of the study was to determine the dose of cyclosporin A (CsA), in combination with doxorubicin (DOX) and ifosfamide (IFX), needed to achieve steady-state whole-blood levels of 2000 ng ml-' and the associated toxicity of this combination. Treatment consisted of CsA 5 mg kg-' as a 2 h loading infusion, followed by a CsA 3 day continuous infusion (c.i.) (days 1 -3) at doses that were escalated from 10 to 18 mg kg-' day-'. 
The expression of the mdrl gene is a well-known mechanism of multidrug resistance in vitro. The product of this gene, P-glycoprotein (P-gp), is present in the membrane of cells of many cancers and normal human tissues (Goldstein et al., 1989; Pastan and Gottesman, 1991) , and belongs to the ATP-binding cassette superfamily of protein transporters. P-gp removes cytotoxins belonging to the multidrug resistance (MDR) phenotype from the cell membrane and from the cytoplasm of the exposed cell. The drugs sharing the MDR mechanism are derivatives of natural products and include epipodophyllotoxins, anthracycines, vinca alkaloids, taxol, actinomycin D and others.
The role of P-gp in clinical resistance has not been clearly established, although it seems that the expression of P-gp influences the response to therapy of certain tumours such as acute leukaemias, neuroblastomas and paediatric sarcomas (Chan et al., 1990 (Chan et al., , 1991 Marie et al., 1991; Pirker et al., 1991; Campos et al., 1992) .
Certain drugs are known to reverse MDR in vitro. One of the most powerful non-cytotoxic agents effective in blocking the function of P-gp is the immunosuppressive drug cyclosporn A (CsA). CsA is a substrate of P-gp and can competitively inhibit this membrane protein at clinically attainable doses. Concentrations of 1000-2000ngml-' CsA are needed to reverse MDR in vitro (Twentyman et al., 1987) . At these doses CsA can also suppress the induction of the DNA repair genes (Kashami-Sabet et al., 1990) and may potentiate the cytotoxicity of antineoplastic agents in human tumour cells not expressing P-gp (Larsson and Mygren, 1990) .
Among actively used antineoplastic agents doxorubicin (DOX) belongs to the classical MDR phenotype whilst ifosfamide (IFX) does not and the latter is not cross-resistant with DOX. Ifosfamide causes glutathione depletion in vitro and in vivo (Lind et al., 1989) . It has also been reported that the cytotoxicity of DOX is enhanced following depletion of glutathione (GSH) levels (Lee et al., 1988 Also, in patients who rcived more than one cycle of treatment, the vahls drawn before the beginning of the last ccle were compared with those obtaied before the first treatment.
Res
The characteristics of the 18 patients treated in this study are shown in Table H . Thirteen patients (72%) had reeived DOX as part of their previous chemotherapy, seven (39%) reived mitoxantrone (DHAD), five (28%) both drugs, and four (22%) etoposide.
Twelve patients (66.6%) had been treated with one chemotherapy programme before entering this protocol, three patients (16.6%) with two different chemotherapy progam mes and three patets (16.6%) with more than two programmes. Ten patients had had radiotherapy. Table V ). T cellfunction studies ( Figure 1I Companrng the different lymphocyte subpopulations seen before and 12 h after every cycle in 14 patients, there were significant decreases in the total lymphocyte counts (P= 0.0002). and in CDl9 (P = 0.0007), CD3 (P = 0.00018). CI4 (P= 0.0164) and CD8 (P= 0.0003) subpopulations. In seven patients who received more than one cycle, basal pretherapy counts were compared in the first and last treatments, with no significant differences in total lymphocyte counts (P=0.8). nor in CD19 (P=0.7). CD3 (P=0.8), CD4 (P= 0.3) and CD8 (P= 0.8) subpopulations. Similarly a significant increase in the CD4 CD8 lymphocyte ratio was detected in 14 patients (P = 0.02). but again no differences were observed between the first and the last cycle of therapy in seven patients with more than one cycle (P = 1.0). In 12 patients. PHA LTI showed no significant differences between basal and post-treatment values (P = 0.75). In five patients who received more than one cycle. the value of basal LTI before the first cvcle was similar to the value obtained before the last cycle (P = 0.50).
Responses
There were two objective remissions (11%)o95% confidence intervals 1.38-34.71%). One patient (treated with CsA c.i. at 16 mg kg-' day-) with an epidermoid carcinoma of the cervix with pulmonary and bone metastases, had a PR lasting 2.5 months and another patient (treated with CsA c.i. at 14 mg kg-' day-') with metastatic Ewing's sarcoma, had a PR lasting 8 months.
Curiously. two patients (one with breast cancer and another with soft tissue sarcoma) who experienced PD showed a decrease of more than 50% in the size of isolated metastatic lesions with simultaneous increase of other lesions.
Finally, another patient (treated with CsA c.i. at 14 mg kg-' day-') with metastatic breast cancer showed symptomatic pain relief and improvement in performance status without objective response in measurable tumour for 6 months.
Disuson
Preliminary studies (Rodenburg et al.. 1991; Verweij et al., 1991) using CsA as a modifier of drug resistance in combination with MDR cytotoxins in colon and renal carcinomas. showed that CsA levels of 1000-2000 ng ml-' could be achieved in the clinic with acceptable toxicity, although no activity was observed using this approach in such tumour types. These tumours are also resistant to many anti-cancer drugs which are not MDR related, including ifosfamide. Owing to the negative results of these trials and the intrinsic (Awni. 1992 ). In such situations, CsA also decreases the LTI (Awni. 1992 several lymphocyte subsets and the LTI associated with intermittent high doses of CsA and chemotherapy. We have shown that short-term variations (a signifint decrease in the CD3, CD4, CD8 and CDl9 subpopulation counts) really occur early after treatment, and that these changes are reversible. This is shown in the patients who received more than one treatment cycle and yet did not show a signnt decrease in the lymphocyte subpopulations studied. The LTI was not significantly modified by this treatment, either early after treatment or later. In addition, no opportunisc infections were observed. Taken together these results appear to suggest that this treatment can be safely inistered without inducing a significant immunosuppressive status.
In contrast with the tendency of CsA and different schedules of combination chemotherapy to reduce the number of CD4 cells to a greater extent than CD8 cells, resulting in a decrease of the CD4/CD8 ratio (Olsen et al., 1988; Favrot et al., 1983; Linch et al., 1983; Onsrud et al., 1986) , we have documented a signifint increase of the CD4/CD8 ratio early after treatment with this protocol. We do not know whether such smalkr CD4 decreases in comparison with CD8 cells occurring early after treatment may be considered a result of an effective modulation of the P-gp expressed by these lymphocyte subpopulations. Recent studies have evaluated the expression and activity of P-gp in human subpopulations of normal peripheral blood and bone marrow cells (Chaudhary et al., 1992; Drach et al., 1992) . A functional P-gp was found to be expressed in all peripheral blood subpopulations (CD4, CD8, CD14, CD19, CD56) except granulocytes. In the study of Chaudhary et al. (1992) , P-gp was expressed in the majority of the CD8, CD56 and CD20 peripheral blood cells (60-90%), but only in kss than one-half of CD4 cells. Although an effective modulation of DOX by high doses of CsA explains our observations regarding the increase in the CD4/CD8 ratio, alternative explanations may be greater CD8 cell sensitivity to chemotherapy (than CD4 cells) and/or that CD8 cells have shorter survival times. The toxicities observed with our protocol were similar to those reported m other phase I trals with intemttent high doses of CsA given as modifier of drug resistance (Yahanda et al., 1992; Erlichman et al., 1993; List et al., 1993) . Such toxicities were: hyperbiirubinm (46% cycles), hypomagnesaemia (72% of cycles), hypertension (15%), nephrotoxicity (20%) and mild to moderate fluid retention (100%). Hypomagnesaemia was easily manaeable and no clinical symptomatology was seen. Nephrotoxicity was mild and reversible in five patients. Three of them had received prior treatment with cisplatin, and a possible predisposition to experience nephrotoxicity in these patients cannot be discarded. Neverthelss, we have observed a similar incidence of this toxicty as compared with other recently pubished series (Yahanda et al., 1992; Edichman et al., 1993) , and no episodes of acute renal failure have been observed. Two patients obtained a PR with our protocol. Interestingly, one of them was a patient with Ewing's sarcoma who was progressing after treatment with the same drugs without CsA. The addition of CsA to the same agents that faied previously induced a PR. This patient presented acquired istance to prior DOX-based chemotherapy. It remains to be elaborated whether adequate levels of CsA reached the tumour cells, in our study as well as past studies.
The inaccessability of metastatic lesions in most of our cases precluded tumour biopsy for determination of CsA. At present, it is not known whether adequate plasma levels of CsA are associated with good intratumour levels. It would be convenient to address such question in the design of future studies with CsA, although feasibility may constitute a significnt problem in solid tumours.
In summary, CsA steady-state levels of 2000 ng ml-I can be achieved with a loading dose of 5 mg kg-1 followed by a 3 day CsA c.i. at a dose of 16mgkg-' day-' in combination with DOX and IFX, with accptable toxicity. Although some encouraging resonses have been observed, and an attempt to modulate resistance by different mechanisms appears interesting, further evaluation is needed to establish the clinical value of this approach in seected tumour types.
